EPRX
Q3 2026 EPS Estimate
$-0.26
Reports before open

Analyst Sentiment

Wall St. Consensus
Buy
2 analysts·Low coverage
75
Score
2 Buy (100%)0 Hold (0%)0 Sell (0%)
Rating Breakdown
Strong Buy
00%
Buy
2100%
Hold
00%
Sell
00%
Strong Sell
00%

Analyst ratings reflect Wall Street opinion, not guarantees. Historical accuracy varies by firm and sector.

Price Target Expectations

Bear
$19.00
+175.4%
Consensus
$19.00
+175.4%
Bull
$19.00
+175.4%
12-Month Target Range2 analysts
$19.00$19.00$19.00
Current $6.90Consensus
Current Price
$6.90
Upside to Consensus
$12.10

Price targets are 12-month analyst forecasts. Actual results depend on earnings, market conditions, and sector trends.

Earnings & Revenue Estimates

Forward Growth Estimates (YoY)
FY2027
Rev
EPS
FY2028
Rev-62.45%
EPS
FY2029
Rev
EPS

Earnings Surprises

Recent Analyst Actions

Jan 15, 2026Cantor Fitzgerald
Eupraxia Pharmaceuticals price target raised to $19 from $11 at Cantor Fitzgerald
Target:$19.00
+125.4%from $8.43